Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Integrative Biology : Quantitative Biosciences From Nano to Macro|May 23, 2015
MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cellsChorom Pak, Natalie S Callander, Edmond W K Young, et al.
JAMA Oncology|January 6, 2018
Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysisBinod Dhakal, Aniko Szabo, Saurabh Chhabra, et al.
British Journal of Haematology|December 21, 2012
MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophagesEllen Hebron, Chelsea Hope, Jaehyup Kim, et al.
American Journal of Cancer Research|January 26, 2016
Tumor-selective anti-cancer effects of the synthetic alkyl phosphocholine analog CLR1404 in neuroblastomaRoberta Marino, Dana C Baiu, Saswati Bhattacharya, et al.
Blood|June 5, 2016
Immunoregulatory roles of versican proteolysis in the myeloma microenvironmentChelsea Hope, Simon Foulcer, Justin Jagodinsky, et al.
Cancer Immunology Research|May 6, 2015
Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple MyelomaJeffrey Lee Jensen, Alexander Rakhmilevich, Erika Heninger, et al.
The Journal of Clinical Investigation|December 9, 2014
LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesisShi-Dong Ma, Xuequn Xu, Julie Plowshay, et al.
The Journal of Biological Chemistry|December 28, 2017
Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myelomaMailee Huynh, Chorom Pak, Stephanie Markovina, et al.
Scientific Reports|June 23, 2022
Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ modelEvan Flietner, Zhi Wen, Adhithi Rajagopalan, et al.
Oncogene|April 8, 2023
Molecular characterization stratifies VQ myeloma cells into two clusters with distinct risk signatures and drug responsesEvan Flietner, Mei Yu, Govinda Poudel, et al.
Pageof 6